Thanks for sharing your interpretation, RRDog. Something that comes to mind is that the fixing of the preferred offering terms works in tandem with fixing posting on this board into a new venue. Conversion of preferred shares to common brings voting rights that in turn, can bring about major institutional holding of the Common, depending on what Institutions choose to pick up the PPHMP shares. Absent partnering or buyout, PPHM is embarking on a go it alone funding strategy. If the Preferred offering brings in enough funding for the completion of the Sunrise trial, shareholders can focus on whether Fast Track approval from the FDA can be utilized with the delivery of favorable trial results. And so does the business plan milestone snowball effect get bigger as critical PPHM events are picked up. The new venue is that retail shareholders may no longer be the collective largest holder of common shares as terms of the preferred offering are set and ownership is revealed.
As has always been the case, the PPHM technology needs to perform if share price expectations are to be delivered.
Best wishes and IMO.
KT
News 
Market Data 
Discover 
